Second-line weekly docetaxel in advanced non-small cell lung cancer

M. Serke, D. Argiropulos, N. Schoenfeld, R. Loddenkemper (Berlin, Germany)

Source: Annual Congress 2001 - Therapy for non-small cell lung cancer
Session: Therapy for non-small cell lung cancer
Session type: Poster Discussion
Number: 2580

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
M. Serke, D. Argiropulos, N. Schoenfeld, R. Loddenkemper (Berlin, Germany). Second-line weekly docetaxel in advanced non-small cell lung cancer. Eur Respir J 2001; 16: Suppl. 31, 2580

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Second-line weekly paclitaxel in advanced nonsmall cell lung cancer (NSCLC)
Source: Annual Congress 2003 - Advanced lung cancer treatment
Year: 2003


Gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer
Source: Eur Respir J 2003; 22: Suppl. 45, 64s
Year: 2003

Docetaxel in combination with cisplatin in patients with advanced non-small cell lung cancer
Source: Eur Respir J 2004; 24: Suppl. 48, 302s
Year: 2004

Docetaxel and carboplatin as the second-line treatment of non-small cell lung cancer
Source: Eur Respir J 2002; 20: Suppl. 38, 464s
Year: 2002

Locally advanced inoperable non-small cell lung cancer (NSCLC) treated by weekly paclitaxel/carboplatin chemotherapy with concomitant radiotherapy
Source: Eur Respir J 2007; 30: Suppl. 51, 433s
Year: 2007

Weekly chemotherapy with cisplatin and paclitaxel in inoperable advanced non-small cell lung cancer: an extended phase II study
Source: Eur Respir J 2005; 26: Suppl. 49, 12s
Year: 2005

Chemotherapy with carboplatin and gemcitabine in patients with non resectable stages of non-small cell lung cancer (non-SCLC)
Source: Eur Respir J 2007; 30: Suppl. 51, 436s
Year: 2007

Phase II study of gemcitabine plus irinotecan as second-line chemotherapy in advanced non-small cell lung cancer
Source: Annual Congress 2009 - Management of thoracic malignancies
Year: 2009

Non-small cell lung cancer - oral navelbine single-agent chemotherapy in elderly patient advanced stage or metastatic disease
Source: Eur Respir J 2004; 24: Suppl. 48, 303s
Year: 2004

Chemotherapy in advanced nonsmall cell lung cancer
Source: Eur Respir Mon; 2009: 44: 271–283
Year: 2009

Vinorelbin and cisplatin in the treatment of advanced stage non-small cell lung cancer: Indian experience
Source: Annual Congress 2008 - Treatment of thoracic tumours
Year: 2008

First- and second-line therapy for advanced nonsmall cell lung cancer
Source: Eur Respir J 2009; 33: 915-930
Year: 2009



Second-line therapy in elderly patients with advanced nonsmall cell lung cancer
Source: Eur Respir J 2014; 43: 240-249
Year: 2004



Chemotherapy with oral vinorelbine for geriatric patients with advanced non-small cell lung cancer – preliminary results
Source: Eur Respir J 2006; 28: Suppl. 50, 752s
Year: 2006

Lung function evaluation in gemcitabine and concurrent radiotherapy treatment in nonsmall cell lung cancer (NSCLC)
Source: Eur Respir J 2001; 18: Suppl. 33, 376s
Year: 2001

The safety and efficacy of treatment with nab-paclitaxel and carboplatin for patients with advanced squamous non-small cell lung cancer with interstitial lung disease.
Source: International Congress 2017 – Lung cancer: clinical research on exhaled breath, clinical trials in advanced NSCLC and real-life appraisals of immunotherapies
Year: 2017



Consolidation maintenance oral vinorelbine following concurrent chemoradiation of intravenous vinorelbine and cisplatin in patients with unresectable stage III non-small cell lung cancer
Source: International Congress 2015 – Advances in the therapy of lung cancer
Year: 2015

Single agent gemcitabine or docetaxel in the second-line therapy for patients with non-small cell lung cancer previously treated with platin-based chemotherapy
Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life
Year: 2013

Erlotinib and bevacizumab versus cisplatin, gemcitabine and bevacizumab in unselected nonsquamous nonsmall cell lung cancer
Source: Eur Respir J 2015; 46: 219-229
Year: 2015



Biweekly administration of docetaxel and gemcitabine for elderly patients with advanced non-small cell lung cancer (NSCLC). A phase II study
Source: Eur Respir J 2006; 28: Suppl. 50, 772s
Year: 2006